On November 4, GlaxoSmithKline PLC rose 4.09% in Pre-Market Trading, trading at $50.69 per share, with turnover of $2.2683 million.
The clearest fresh catalyst was Alamar Biosciences saying it will use its NULISA platform in a collaboration with GSK to study circulating protein signatures and disease progression, an update that points to continued external innovation activity around GSK’s research platform.
The announcement arrived after GSK’s late-October third-quarter report, in which revenue rose 4% to 8.89 billion pounds and the company reaffirmed full-year guidance for 3% to 5% revenue growth and 7% to 9% core EPS growth. That results backdrop was mixed, with specialty medicines showing double-digit growth while vaccines softened, and it was followed by cautious analyst actions including a Jefferies downgrade to Hold and an RBC target-price cut on the London listing.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments